The co-administration of PD-L1 siRNA with a DC-based mRNA vaccination is an intriguing new strategy that boosted anti-tumour responses by downregulating PD-L1 in tumour-antigen-presenting DCs [40]. This evidence concerns the gene CD274 and neoplasm.